The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Fulcrum Therapeutics, Inc. (NasdaqGM: FULC) securities between March 3, 2022 and March 8, 2023.
According to the Fulcrum lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) the preclinical data submitted in support of FTX-6058 (an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies) showed safety concerns regarding potential hematological malignancies; (ii) the foregoing safety concerns increased the likelihood that the FDA would place a clinical hold on preclinical studies of FTX-6058; (iii) accordingly, the Company had overstated FTX-6058’s clinical and/or commercial prospects; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Fulcrum you have until June 27, 2023 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
To receive more information, please fill out the form.